<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2112">
  <stage>Registered</stage>
  <submitdate>23/09/2008</submitdate>
  <approvaldate>23/09/2008</approvaldate>
  <nctid>NCT00759200</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients</studytitle>
    <scientifictitle>An Open-label, Randomized, Multicenter, Active-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of Albinterferon Alfa 2b Administered Every 4 Weeks Plus Ribavirin in Interferon Alfa-naïve Patients With Genotype 2/3 Chronic Hepatitis C</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CABF656B2202</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - alb-interferon alfa 2b
Treatment: drugs - alb-interferon alfa 2b
Treatment: drugs - alb-interferon alfa 2b
Treatment: drugs - alb-interferon alfa 2b
Treatment: drugs - peg-interferon

Experimental: alb-interferon arm 1 - 

Experimental: alb-interferon arm 2 - 

Experimental: alb-interferon arm 3 - 

Experimental: alb-interferon arm 4 - 

Active Comparator: peg-interferon - 


Treatment: drugs: alb-interferon alfa 2b
900 mcg every 4 weeks

Treatment: drugs: alb-interferon alfa 2b
1200 mcg every 4 weeks

Treatment: drugs: alb-interferon alfa 2b
1500 mcg every 4 weeks

Treatment: drugs: alb-interferon alfa 2b
1800 mcg every 4 weeks

Treatment: drugs: peg-interferon
Peg-interferon alfa 2a: 180 mcg 1x per wk.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint>at every visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Viral load</outcome>
      <timepoint>at weeks 4, 12 and 24 of treatment and 24 weeks post-treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age of 18 years or older

          -  Clinical diagnosis of chronic hepatitis C

          -  Infection with HCV genotype 2 or 3

          -  No previous IFNa-based therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women of child-bearing potential if not using double barrier method of contraception,
             pregnant or nursing

          -  Fertile males, unless condom with spermicide is used and female partner agrees to use
             one or more of the acceptable methods until 7 months after last dose of RBV

          -  History or current evidence of decompensated liver disease; other forms of liver
             disease

          -  Coinfection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  History of moderate, severe or uncontrolled psychiatric disease

          -  History of seizure disorder

          -  History or clinical evidence of chronic cardiac disease, preexisting interstitial lung
             disease or severe lung disease

          -  Clinically significant findings on eye/retinal examination

          -  History of immunologically mediated disease

          -  Organ transplantation other than cornea or hair transplant

          -  History of clinically significant hemoglobinopathy

          -  Diagnosis of malignancy of any organ system with the exception of localized basal cell
             carcinoma of the skin

          -  History of galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption

          -  History of hypersensitivity to any of the study drugs or to drugs with similar
             chemical structures

          -  Drug or alcohol addiction within the last 6 months and/or positive drug screening
             tests

          -  Received systemic corticosteroids (prednisone equivalent of &gt; 10 mg/day) within 14
             days prior to Baseline visit

          -  Received concomitant systemic antibiotics, antifungals or antivirals for the treatment
             of active infection within 14 days prior to Baseline visit.

          -  Received herbal therapies (including milk thistle or glycyrrhizin) or an
             investigational drug within 35 days prior to Baseline visit

          -  Have a clinically significant laboratory abnormality

        Other protocol-defined inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>525</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Novartis Investigative site - Clayton</hospital>
    <hospital>Novartis Investigative site - Fitzroy</hospital>
    <hospital>Novartis Investigative site - Greenslopes</hospital>
    <hospital>Novartis Investigative site - Kingswood</hospital>
    <hospital>Novartis Investigative site - Melbourne</hospital>
    <hospital>Novartis Investigative site - Westmead</hospital>
    <postcode> - Clayton</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Greenslopes</postcode>
    <postcode> - Kingswood</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Downsview</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cretail</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Düsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Loannina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patra-Rio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Piraeurs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chandigarh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Lucknow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Ludhiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Polermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Oviedo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chaingmai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Hat Yai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Muang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Human Genome Sciences Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety and efficacy of alb-interferon in adults with genotype 2
      or 3 chronic hepatitis</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00759200</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>